Michael Tolstorukov

Dana-Farber Cancer Institute

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index48

i10-index74

Publications417

Citations14,147

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 101

Abstract 1850: Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers.
Cancer Research · 2026-04-03
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Zenodo (CERN European Organization for Nuclear Research) · 2026-04-01
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Zenodo (CERN European Organization for Nuclear Research) · 2026-04-01
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy
Blood Advances · 2026-03-19 · 1 citations
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Cancer Cell · 2026-03-05 · 4 citations
Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity
Nature Communications · 2026-02-21 · 3 citations
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
JCI Insight · 2026-01-22
Interpreting the functional impact of genetic variants: The need for context qualifiers
The American Journal of Human Genetics · 2025-12-01 · 3 citations
Supplementary Figure 1 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Figure 6 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Tables 1-8 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Figure 5 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Figure 3 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Figure 4 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Supplementary Figure 2 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
2025-11-25
Atomistic TCR-ligand interactions shape memory T-cell differentiationPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-06
Figure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
2025-11-03
Figure S10 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
2025-11-03
Figure S7 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
2025-11-03
Figure S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
2025-11-03

Open author page on OpenAlex →